Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Hai-Bo Mou"'
Autor:
Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4137-4146 (2023)
Abstract Objective This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background Pem
Externí odkaz:
https://doaj.org/article/33db6e2caae9409c859c394540b3696a
Autor:
Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou
Publikováno v:
Cancer Medicine. 12:4137-4146
This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements.Pemigatinib provided clinical bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942046ddbca0aa5c7674c277496a9b51
https://doi.org/10.1002/cam4.5273
https://doi.org/10.1002/cam4.5273
Publikováno v:
Hepatobiliary & Pancreatic Diseases International. 19:91-93
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfb09069714a9e29835218dee92a09cf
https://doi.org/10.1016/j.hbpd.2019.09.011
https://doi.org/10.1016/j.hbpd.2019.09.011
Autor:
Kai Wang, Hai-Bo Mou, Wendong Li, Yanjun Shen, Ming Yao, Ting Zhang, Xiaodi Guo, Jun-Ping Shi
Publikováno v:
Hepatobiliary & Pancreatic Diseases International. 17:477-479
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::202a914fd258cee8ca41d6a9f893cbe6
https://doi.org/10.1016/j.hbpd.2018.09.011
https://doi.org/10.1016/j.hbpd.2018.09.011
Publikováno v:
GEOPHYSICS. 81:T357-T368
The conventional energy flux density vector indicates the propagation direction of mixed P- and S-wave wavefields, which means when a wavefront of P-wave encounters a wavefront of S-wave with different propagation directions, the vectors cannot indic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f53a6d62baaec91a4ba4bba9c784f101
https://doi.org/10.1190/geo2016-0245.1
https://doi.org/10.1190/geo2016-0245.1
Publikováno v:
Journal of Highway and Transportation Research and Development (English Edition). 9:71-78
Most research on travel time reliability (TTR) is from the perspective of the road managers. Therefore, dynamic TTR from the view of road users is proposed. The concept considers the influence of random road network variations on road users. Two dime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b2d2476108d10c9539f8d48f2d93ba0
https://doi.org/10.1061/jhtrcq.0000427
https://doi.org/10.1061/jhtrcq.0000427
Autor:
Lan-Fang Yu, Lingjian Wang, Yinfang Wu, Kai Wang, Ming Yao, Qiang Cui, Ruobing Ma, Hai-Bo Mou, Qin Liao, Na Yan, Xuehua Hou
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-5 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-5 (2018)
Background Cholangiocarcinoma, or bile duct cancer, is a gastrointestinal cancer with limited therapeutic options and a poor outcome. Studies have revealed that some major driver genes are associated with cholangiocarcinoma, but no targeted therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27271df783c9865d425ddb1ebb383c69
https://pubmed.ncbi.nlm.nih.gov/30419854
https://pubmed.ncbi.nlm.nih.gov/30419854
Autor:
Zhe Yang, Ming Yao, Xiao Liang, Junping Shi, Xiaoqian Chen, Lingxiang Liu, Daobing Zeng, Zhe Wan, Junjie Xu, Zhonghai Chen, Hai-Bo Mou, Shi Jiang, Kai Wang
Publikováno v:
Journal of Clinical Oncology. 37:e15666-e15666
e15666 Background: Hepatocellular carcinoma (HCC) has a high mortality rate and is the fourth most common cancer in China. Immunotherapy of immune checkpoint inhibitors (ICI) is a promising novel treatment strategy, but the response rate is generally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebff97c262b88522bc9707988a3e2bbf
https://doi.org/10.1200/jco.2019.37.15_suppl.e15666
https://doi.org/10.1200/jco.2019.37.15_suppl.e15666
Autor:
Hai Bo Mou, Xiao Chen Zhang, Wei Jia Fang, Jin Chen, Jing Deng, Sui Huang, Peng Shen, Nong Xu, Lan Fang Yu, Han Ying Bao, Gen Ming Shi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:147-152
To evaluate the efficacy and safety of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.The FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m(2) on day 1 plus leucovorin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5a71c232cdac66afd2d156b9301ce9
https://doi.org/10.1007/s00280-010-1301-5
https://doi.org/10.1007/s00280-010-1301-5
Autor:
Jing Deng, Xiao Chen Zhang, Bin Bin Chu, Jing Chen, Hong Ming Fang, Jiong Qian, Hai Bo Mou, Dong Ping Wu, Li Song Teng, Nong Xu, Wei Jia Fang
Publikováno v:
Medical oncology (Northwood, London, England). 29(2)
A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. Chinese female patients with locally advanced or metastatic NSCLC who failed at least o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6fc66356e7d91b0f661879a4ec66655
https://pubmed.ncbi.nlm.nih.gov/21399997
https://pubmed.ncbi.nlm.nih.gov/21399997